MAAT fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. It engages to restore and modulate patient-microbiome symbiosis to improve survival in cancer. The company develops microbiome drug candidates: Microbiome Ecosystem Therapies which are high-diversity, high-richness, indication-specific products aiming to leverage the full functional diversity of a microbiome ecosystem. The company was founded by Herve Affagard, Joel Dore, Mohamad Mohty, Pierre Rimbaud and Pierre Belichard in 2014 and is headquartered in Lyon, France.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
MAAT does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company